<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37415915</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-861X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in nutrition</Title><ISOAbbreviation>Front Nutr</ISOAbbreviation></Journal><ArticleTitle>Refueling the post COVID-19 brain: potential role of ketogenic medium chain triglyceride supplementation: an hypothesis.</ArticleTitle><Pagination><StartPage>1126534</StartPage><MedlinePgn>1126534</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1126534</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fnut.2023.1126534</ELocationID><Abstract><AbstractText>COVID-19 infection causes cognitive changes in the acute phase, but also after apparent recovery. Over fifty post (long)-COVID symptoms are described, including cognitive dysfunction ("brain fog") precluding return to pre-COVID level of function, with rates twice as high in females. Additionally, the predominant demographic affected by these symptoms is younger and still in the workforce. Lack of ability to work, even for six months, has significant socio-economic consequences. This cognitive dysfunction is associated with impaired cerebral glucose metabolism, assessed using <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography (FDG-PET), showing brain regions that are abnormal compared to age and sex matched controls. In other cognitive conditions such as Alzheimer's disease (AD), typical patterns of cerebral glucose hypometabolism, frontal hypometabolism and cerebellar hypermetabolism are common. Similar FDG-PET changes have also been observed in post-COVID-19, raising the possibility of a similar etiology. Ketone bodies (B-hydroxybutyrate, acetoacetate and acetone) are produced <i>endogenously</i> with very low carbohydrate intake or fasting. They improve brain energy metabolism in the face of cerebral glucose hypometabolism in other conditions [mild cognitive impairment (MCI) and AD]. Long-term low carbohydrate intake or prolonged fasting is not usually feasible. Medium chain triglyceride (MCT) is an <i>exogenous</i> route to nutritional ketosis. Research has supported their efficacy in managing intractable seizures, and cognitive impairment in MCI and AD. We hypothesize that cerebral glucose hypometabolism associated with post COVID-19 infection can be mitigated with MCT supplementation, with the prediction that cognitive function would also improve. Although there is some suggestion that post COVID-19 cognitive symptoms may diminish over time, in many individuals this may take more than six months. If MCT supplementation is able to speed the cognitive recovery, this will impact importantly on quality of life. MCT is readily available and, compared to pharmaceutical interventions, is cost-effective. Research shows general tolerability with dose titration. MCT is a component of enteral and parenteral nutrition supplements, including in pediatrics, so has a long record of safety in vulnerable populations. It is not associated with weight gain or adverse changes in lipid profiles. This hypothesis serves to encourage the development of clinical trials evaluating the impact of MCT supplementation on the duration and severity of post COVID-19 cognitive symptoms.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Juby, Cunnane and Mager.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Juby</LastName><ForeName>Angela G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Division of Geriatrics, Department of Medicine, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunnane</LastName><ForeName>Stephen C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Research Center on Aging, Universit&#xe9; de Sherbrooke, Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mager</LastName><ForeName>Diana R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Agriculture Food and Nutrition Science, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Nutr</MedlineTA><NlmUniqueID>101642264</NlmUniqueID><ISSNLinking>2296-861X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">beta-hydroxybutyrate</Keyword><Keyword MajorTopicYN="N">brain fog</Keyword><Keyword MajorTopicYN="N">medium chain triglyceride</Keyword><Keyword MajorTopicYN="N">post (long) COVID-19</Keyword><Keyword MajorTopicYN="N">subjective cognitive decline</Keyword></KeywordList><CoiStatement>SC has consulted for or received travel honoraria or test products from Nestl&#xe9; Health Science, Abbott, and Cargill. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>7</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37415915</ArticleId><ArticleId IdType="pmc">PMC10320593</ArticleId><ArticleId IdType="doi">10.3389/fnut.2023.1126534</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vastag B, Mazur B. (2020). Researchers warn covid-19 could cause debilitating long-term illness in some patients. The Washington Post. Available at: washingtonpost.com/health/could-covid-19-cause-long-term-chronic-fatigue-and-illness-in-some-patients/2020/05/29/bcd5edb2-a02c-11ea-b5c9-570a91917d8d_story.html (Accessed May 30, 2020).</Citation></Reference><Reference><Citation>Kleinman Z. (2020). Coronavirus: thousands say debilitating symptoms last 'for weeks'. BBC News. Available at: bbc.com/news/health-53269391 (Accessed May 30, 2020).</Citation></Reference><Reference><Citation>Carfi A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA (2020) 324:603&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo P, Cuapio A, et al. . More than 50 long-term effects of COVID-19: A systematic review and Meta-analysis. Res Sq. (2021). doi: 10.21203/rs.3.rs-266574/v1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-266574/v1</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review. J Infect Dis. (2022) 226:1593&#x2013;607. doi: 10.1093/infdis/jiac136, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Infect Dis. (2020) 75:e13746. doi: 10.1111/ijcp.13746</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.13746</ArticleId><ArticleId IdType="pmc">PMC7536922</ArticleId><ArticleId IdType="pubmed">32991035</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleki K, Banazadeh M, Saghazadeh A, Rezaei N. The involvement of the central nervous system in patients with COVID-19. Rev Neurosci. (2020) 31:453&#x2013;6. doi: 10.1515/revneuro-2020-0026</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/revneuro-2020-0026</ArticleId><ArticleId IdType="pubmed">32463395</ArticleId></ArticleIdList></Reference><Reference><Citation>The Management Group of the EAN Dementia and Cognitive Disorders Scientific Panel. Toniolo S, Scarioni M, Di Lorenzo F, Hort J, Georges J, et al. . Dementia and COVID-19, a bidirectional liaison: Risk factors, biomarkers, and optimal health care. J Alzheimers Dis. (2021) 82:883&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">34092646</ArticleId></ArticleIdList></Reference><Reference><Citation>Godlee F. Living with covid-19. BMJ. (2020) 370:m3392. doi: 10.1136/bmj.m3703, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3703</ArticleId><ArticleId IdType="pubmed">32967907</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal A, Iqbal K, Arshard Ali SA, Azim D, Farid E, et al. . The COVID-19 sequelae: a cross-sectional evaluation of post-recovery symptoms and the need for rehabilitation of COVID-19 survivors. Cureus. (2021) 13:e13080. doi: 10.7759/cureus.13080, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.13080</ArticleId><ArticleId IdType="pmc">PMC7932827</ArticleId><ArticleId IdType="pubmed">33680620</ArticleId></ArticleIdList></Reference><Reference><Citation>Desforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dub&#xe9; M, et al. . Human corona viruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses. (2019) 12:14. doi: 10.3390/v12010014, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12010014</ArticleId><ArticleId IdType="pmc">PMC7020001</ArticleId><ArticleId IdType="pubmed">31861926</ArticleId></ArticleIdList></Reference><Reference><Citation>Filatov A, Sharma P, Hindi F. Neurological complications of coronavirus disease (COVID-19): encephalopathy. Cureus. (2020) 70:311&#x2013;22. doi: 10.7759/cureus.7352</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.7352</ArticleId><ArticleId IdType="pmc">PMC7170017</ArticleId><ArticleId IdType="pubmed">32328364</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseini S, Wilk E, Michaelsen-Preusse K, Gerhauser I, Baumgartner W, Geffers R, et al. . Long-term Neuroinflammation induced by influenza A virus infection and the impact on hippocampal neuron morphology and function. J Neurosci. (2018) 38:3060&#x2013;80. doi: 10.1523/JNEUROSCI.1740-17.2018, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1740-17.2018</ArticleId><ArticleId IdType="pmc">PMC6596076</ArticleId><ArticleId IdType="pubmed">29487124</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardan L, Filtchev D, Kassem R, Bourgi R, Lukomska-Szymanska M, Tarhini H, et al. . COVID-19 and Alzheimer&#x2019;s disease: A literature review. Medicina. (2021) 57:1159. doi: 10.3390/medicina57111159, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57111159</ArticleId><ArticleId IdType="pmc">PMC8625592</ArticleId><ArticleId IdType="pubmed">34833377</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuovo GJ, Suster D, Sawant D, Mishra A, Michaille JJ, Tili E. The amplification of CNS damage in Alzheimer's disease due to SARS-CoV2 infection. Ann Diagn Pathol. (2022) 61:152057. doi: 10.1016/j.anndiagpath.2022.152057, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anndiagpath.2022.152057</ArticleId><ArticleId IdType="pmc">PMC9616485</ArticleId><ArticleId IdType="pubmed">36334414</ArticleId></ArticleIdList></Reference><Reference><Citation>Cani I, Barone V, D&#x2019;Angelo R, Pisani L, Allegri V, et al. . Frontal encephalopathy related to hyperinflammation in COVI-19. J Neurol. (2020) 268:16&#x2013;9. doi: 10.1007/s00415-020-10057-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10057-5</ArticleId><ArticleId IdType="pmc">PMC7353824</ArticleId><ArticleId IdType="pubmed">32654063</ArticleId></ArticleIdList></Reference><Reference><Citation>Delorme C, Paccoud O, Kas A, Hesters A, Bombois S, Shambrook P, et al. . COVID-19 related encephalopathy: A case series with brain FDG-PET/CT findings. Eur J Neurol. (2020) 27:2651&#x2013;7. doi: 10.1111/ene.14478, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14478</ArticleId><ArticleId IdType="pmc">PMC7461074</ArticleId><ArticleId IdType="pubmed">32881133</ArticleId></ArticleIdList></Reference><Reference><Citation>Daulatzai MA. Cerebral hypoperfusion and glucose hypometabolism: key pathological modulators promote neurodegeneration, cognitive impairment, and Alzheimer&#x2019;s disease. J Neurosci Res. (2017) 95:943&#x2013;72. doi: 10.1002/jnr.23777, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23777</ArticleId><ArticleId IdType="pubmed">27350397</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, Million M, Dudouet P, Tissot-Dupont H, Bregeon F, Cammilleri S, et al. . 18F-FDG brain PET hypometabolism in postSARS-CoV-2 infection: substrate for persistent/delayed disorders? Eur J Nucl Med Mol Imaging. (2020) 48:592&#x2013;5. doi: 10.1007/s00259-020-04973-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-04973-x</ArticleId><ArticleId IdType="pmc">PMC7391029</ArticleId><ArticleId IdType="pubmed">32728799</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. . Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. (2020) 382:2268&#x2013;70. doi: 10.1056/NEJMc2008597, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2008597</ArticleId><ArticleId IdType="pmc">PMC7179967</ArticleId><ArticleId IdType="pubmed">32294339</ArticleId></ArticleIdList></Reference><Reference><Citation>An Y, Varma VR, Varma S, et al. . Evidence for brain glucose dysregulation in Alzheimer&#x2019;s disease. Alzheimers Dement. (2018) 14:318&#x2013;29. doi: 10.1016/j.jalz.2017.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.09.011</ArticleId><ArticleId IdType="pmc">PMC5866736</ArticleId><ArticleId IdType="pubmed">29055815</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei E, Vacy K, Boon WC. Fatty acids and their therapeutic potential in neurological disorders. Neurochem Int. (2016) 95:75&#x2013;84. doi: 10.1016/j.neuint.2016.02.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2016.02.014</ArticleId><ArticleId IdType="pubmed">26939763</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, et al. . Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. (2020) 19:609&#x2013;33. doi: 10.1038/s41573-020-0072-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-0072-x</ArticleId><ArticleId IdType="pmc">PMC7948516</ArticleId><ArticleId IdType="pubmed">32709961</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortier M, Castellano CA, St-Pierre V, Myette-C&#xf4;t&#xe9; &#xc9;, Langlois F, Roy M, et al. . A ketogenic drink improves cognition in mild cognitive impairment: results of a 6-month RCT. Alz Demen. (2020) 15:625&#x2013;34. doi: 10.1002/alz.12206</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12206</ArticleId><ArticleId IdType="pmc">PMC8048678</ArticleId><ArticleId IdType="pubmed">33103819</ArticleId></ArticleIdList></Reference><Reference><Citation>Croteau E, Castellano CA, Richard MA, Fortier M, Nugent S, Lepage M, et al. . Ketogenic medium chain triglycerides increase brain energy metabolism in Alzheimer&#x2019;s disease. J Alzheimers Dis. (2018) 64:551&#x2013;61. doi: 10.3233/JAD-180202, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180202</ArticleId><ArticleId IdType="pubmed">29914035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendersen ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Constantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer&#x2019;s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab. (2009) 9:6&#x2013;31. doi: 10.1186/1743-7075-6-31</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-7075-6-31</ArticleId><ArticleId IdType="pmc">PMC2731764</ArticleId><ArticleId IdType="pubmed">19664276</ArticleId></ArticleIdList></Reference><Reference><Citation>Juby AG, Blackburn TE, Mager DR. Use of medium chain triglyceride (MCT) oil in subjects with Alzheimer's disease: A randomized, double-blind, placebo-controlled, crossover study, with an open-label extension. Alzheimer's Dementia. (2022) 8:e12259. doi: 10.1002/trc2.12259, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12259</ArticleId><ArticleId IdType="pmc">PMC8919247</ArticleId><ArticleId IdType="pubmed">35310527</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefano GB, Ptacek R, Ptackova H, Martin A, Kream RM. Selective neuronal mitochondrial targeting in SARS-CoV-2 infection affects cognitive processes to induce 'Brain Fog' and results in behavioral changes that favor viral survival. Med Sci Monit. (2021) 27:e930886. doi: 10.12659/MSM.930886, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.930886</ArticleId><ArticleId IdType="pmc">PMC7845145</ArticleId><ArticleId IdType="pubmed">33487628</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunnane SC, Courchesne-Loyer A, Vandenberghe C, St-Pierre V, Fortier M, Hennebelle M, et al. . Can ketones help rescue brain fuel supply in later life? Implications for cognitive health during aging and the treatment of Alzheimer&#x2019;s disease. Front Mol Neurosci. (2016) 9:53. doi: 10.3389/fnmol.2016.00053, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2016.00053</ArticleId><ArticleId IdType="pmc">PMC4937039</ArticleId><ArticleId IdType="pubmed">27458340</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin K, Khabbush A, Williams S, Eaton S, Orford M, Cross JH, et al. . Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders. Lancet Neurol. (2018) 17:84&#x2013;93. doi: 10.1016/S1474-4422(17)30408-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30408-8</ArticleId><ArticleId IdType="pubmed">29263011</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF. Brain metabolism during fasting. J Clin Invest. (1967) 46:1589&#x2013;95. doi: 10.1172/JCI105650, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI105650</ArticleId><ArticleId IdType="pmc">PMC292907</ArticleId><ArticleId IdType="pubmed">6061736</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol. (2013) 304:H1060&#x2013;76. doi: 10.1152/ajpheart.00646.2012, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00646.2012</ArticleId><ArticleId IdType="pmc">PMC3625904</ArticleId><ArticleId IdType="pubmed">23396451</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen NJ, Wodschow HZ, Nilsson M, Rungby J. Effects of ketone bodies on brain metabolism and function in neurodegenerative diseases. Int J Mol Sci. (2020) 21:8767. doi: 10.3390/ijms21228767, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21228767</ArticleId><ArticleId IdType="pmc">PMC7699472</ArticleId><ArticleId IdType="pubmed">33233502</ArticleId></ArticleIdList></Reference><Reference><Citation>Drenick EJ, Alvarez LC, Tamasi GC, Brickman AS. Resistance to symptomatic insulin reactions after fasting. J Clin Invest. (1972) 51:2757&#x2013;62. doi: 10.1172/JCI107095, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI107095</ArticleId><ArticleId IdType="pmc">PMC332976</ArticleId><ArticleId IdType="pubmed">5056667</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasselbach SG, Madsen PL, Hageman LP, Olsen KS, Justesen N, Holm S, et al. . Changes in cerebral blood flow and carbohydrate metabolism during acute hyperketonemia. Am J Phys. (1996) 270:E746&#x2013;51. doi: 10.1152/ajpendo.1996.270.5.E746, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.1996.270.5.E746</ArticleId><ArticleId IdType="pubmed">8967461</ArticleId></ArticleIdList></Reference><Reference><Citation>Corchesne Loyer A, Croteau E, Castellano CA, St Pierre V, Hennebelle M, Cunnane SC. Inverse relationship between brain ketone metabolism in adults during short-term moderate dietary ketosis: A dual tracer quantitative positron emission tomography study. JCBFM. (2017) 37:2485&#x2013;93. doi: 10.1177/0271678X16669366</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X16669366</ArticleId><ArticleId IdType="pmc">PMC5531346</ArticleId><ArticleId IdType="pubmed">27629100</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent S, Croteau E, Pifferi F, Fortier M, Tremblay S, Turcotte E, et al. . Brain and systemic glucose metabolism in the healthy elderly following fish oil supplementation. PLEFA. (2011) 85:287&#x2013;91. doi: 10.1016/j.plefa.2011.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plefa.2011.04.008</ArticleId><ArticleId IdType="pubmed">21795034</ArticleId></ArticleIdList></Reference><Reference><Citation>Croteau E, Castellano CA, Fortier M, Bocti C, Fulop T, Plaquet N, et al. . A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer&#x2019;s disease. Exp Gerontol. (2018) 107:18&#x2013;26. doi: 10.1016/j.exger.2017.07.004, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2017.07.004</ArticleId><ArticleId IdType="pubmed">28709938</ArticleId></ArticleIdList></Reference><Reference><Citation>Caprio M, Infante M, Moriconi E, Armani A, Fabbri A, Mantovani G, et al. . Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian society of endocrinology (SIE). J Endocrinol Inv. (2019) 42:1365&#x2013;86. doi: 10.1007/s40618-019-01061-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-019-01061-2</ArticleId><ArticleId IdType="pubmed">31111407</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor MK, Sullivan DK, Mahnken JD, Burns JM, Swerdlow RH. Feasibility and efficacy data from a ketogenic diet intervention in Alzheimer&#x2019;s disease. Alz Dem Transl Res Clin Interven. (2018) 4:28&#x2013;36. doi: 10.1016/j.trci.2017.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2017.11.002</ArticleId><ArticleId IdType="pmc">PMC6021549</ArticleId><ArticleId IdType="pubmed">29955649</ArticleId></ArticleIdList></Reference><Reference><Citation>Newport MT, Van Itallie TB, Kashiwaya Y, King MT, Veech RL. A new way to produce hyperketonemia: use of ketone monoester in a case of Alzheimer&#x2019;s disease. Alz Demen. (2015) 11:99&#x2013;103. doi: 10.1016/j.jalz.2014.01.006, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.01.006</ArticleId><ArticleId IdType="pmc">PMC4300286</ArticleId><ArticleId IdType="pubmed">25301680</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebello CJ, Keller JN, Liu AG, Johnson WD, Greenway FL. Pilot feasibility and safety examining the effect of medium chain triglyceride supplementation in subjects with mild cognitive impairment: a randomized controlled trial. BBA Clin. (2015) 3:123&#x2013;5. doi: 10.1016/j.bbacli.2015.01.001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbacli.2015.01.001</ArticleId><ArticleId IdType="pmc">PMC4669977</ArticleId><ArticleId IdType="pubmed">26675661</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Zhang Y, Zhang X, Liu L, Zhou B, Mo R, et al. . Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4&#x2212;/&#x2212;: a double-blind, randomized, placebo-controlled crossover trial. Clin Nutr. (2020) 39:2092&#x2013;105. doi: 10.1016/j.clnu.2019.10.017, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2019.10.017</ArticleId><ArticleId IdType="pubmed">31694759</ArticleId></ArticleIdList></Reference><Reference><Citation>Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, et al. . Effect of B-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging. (2004) 25:311&#x2013;4. doi: 10.1016/S0197-4580(03)00087-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(03)00087-3</ArticleId><ArticleId IdType="pubmed">15123336</ArticleId></ArticleIdList></Reference><Reference><Citation>Juby AG, Brocks DR, Jay DA, Davis CMJ, Mager DR. Assessing the impact of factors that influence the ketogenic response to varying doses of medium chain triglyceride (MCT) oil. J Prev Alz Dis. (2021) 1:19&#x2013;28. doi: 10.14283/jpad.2020.53</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2020.53</ArticleId><ArticleId IdType="pubmed">33336220</ArticleId></ArticleIdList></Reference><Reference><Citation>St-Pierre V, Vandenberghe C, Lowry CM, Fortier M, Castellano CA, Wagner R, et al. . Plasma ketone and medium chain fatty acid response in humans consuming different medium chain triglycerides during a metabolic study day. Front Nutr. (2019) 6:46. doi: 10.3389/fnut.2019.00046, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2019.00046</ArticleId><ArticleId IdType="pmc">PMC6481320</ArticleId><ArticleId IdType="pubmed">31058159</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes SD, Kanabus M, Anderson G, Hargreaves IP, Rutherford T, Donnell MO, et al. . The ketogenic diet component decanoic acid increases mitochondrial citrate synthase and complex I activity in neuronal cells. J Neurochem. (2014) 129:426&#x2013;33. doi: 10.1111/jnc.12646, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12646</ArticleId><ArticleId IdType="pubmed">24383952</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebert D, Haller RG, Walton ME. Energy contribution of octanoate to intact rat brain metabolism measured by 13C nuclear magnetic resonance spectroscopy. J Neurosci. (2003) 23:5928&#x2013;35. doi: 10.1523/JNEUROSCI.23-13-05928.2003, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-13-05928.2003</ArticleId><ArticleId IdType="pmc">PMC6741266</ArticleId><ArticleId IdType="pubmed">12843297</ArticleId></ArticleIdList></Reference><Reference><Citation>Han FY, Conboy-Schmidt L, Rybachuk G, Volk HA, Zanghi B, Pan Y, et al. . Dietary medium chain triglycerides for management of epilepsy: new data from human, dog, and rodent studies. Epilepsia. (2021) 62:1790&#x2013;806. doi: 10.1111/epi.16972, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/epi.16972</ArticleId><ArticleId IdType="pmc">PMC8453917</ArticleId><ArticleId IdType="pubmed">34169513</ArticleId></ArticleIdList></Reference><Reference><Citation>Wla&#x17a; P, Soca&#x142;a K, Nieoczym D, &#x141;uszczki JJ, &#x17b;arnowska I, &#x17b;arnowski T, et al. . Anticonvulsant profile of caprylic acid, a main constituent of the medium-chain triglyceride (MCT) ketogenic diet, in mice. Neuropharmacology. (2012) 62:1882&#x2013;9. doi: 10.1016/j.neuropharm.2011.12.015, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2011.12.015</ArticleId><ArticleId IdType="pubmed">22210332</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoeler NE, Orford M, Vivekananda U, Simpson Z, Van de Bor B, Smith H, et al. . Vita: a feasibility study of a blend of medium chain triglycerides to manage drug-resistant epilepsy. Brain Communications. (2021) 3:fcab160. doi: 10.1093/braincomms/fcab160, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab160</ArticleId><ArticleId IdType="pmc">PMC8557697</ArticleId><ArticleId IdType="pubmed">34729477</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan JY, Yoon BK, Cho NJ, Lovri&#x107; J, Jug M, Jackman JA. Lipid nanoparticle technology for delivering biologically active fatty acids and monoglycerides. Int J Mol Sci. (2021) 22:9664. doi: 10.3390/ijms22189664, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22189664</ArticleId><ArticleId IdType="pmc">PMC8465605</ArticleId><ArticleId IdType="pubmed">34575831</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenberghe C, St-Pierre V, Fortier M, Castellano CA, Cuenoud B, Cunnane SC. Medium chain triglycerides modulate the ketogenic effect of a metabolic switch. Front Nutr. (2020) 7:3. doi: 10.3389/fnut.2020.00003</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2020.00003</ArticleId><ArticleId IdType="pmc">PMC7005013</ArticleId><ArticleId IdType="pubmed">32083091</ArticleId></ArticleIdList></Reference><Reference><Citation>Cober MP, Gura KM, Mirtallo JM, Ayers P, Boullata J, Anderson CR, et al. . ASPEN lipid injectable emulsion safety recommendations part 2: neonate and pediatric considerations. Nutr Clin Pract. (2021) 36:1106&#x2013;25. doi: 10.1002/ncp.10778, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ncp.10778</ArticleId><ArticleId IdType="pubmed">34705289</ArticleId></ArticleIdList></Reference><Reference><Citation>Myette-C&#xf4;t&#xe9; &#xc9;, St-Pierre V, Beaulieu S, Castellano CA, Fortier M, Plourde M, et al. . The effect of a 6-month ketogenic medium-chain triglyceride supplement on plasma cardiometabolic and inflammatory markers in mild cognitive impairment. Prostaglandins Leukot Essent Fat Acids. (2021) 169:102236. doi: 10.1016/j.plefa.2020.102236</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plefa.2020.102236</ArticleId><ArticleId IdType="pubmed">33906081</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen JV, Westi EW, Neal ES, Aldana BI, Borges K. &#x3b2;-Hydroxybutyrate and medium-chain fatty acids are metabolized by different cell types in mouse cerebral cortex slices. Neurochem Res. (2023) 48:54&#x2013;61. doi: 10.1007/s11064-022-03726-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-022-03726-6</ArticleId><ArticleId IdType="pubmed">35999339</ArticleId></ArticleIdList></Reference><Reference><Citation>Achanta LB, Rae CD. &#x3b2;-Hydroxybutyrate in the brain: one molecule, multiple mechanisms. Neurochem Res. (2017) 42:35&#x2013;49. doi: 10.1007/s11064-016-2099-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-016-2099-2</ArticleId><ArticleId IdType="pubmed">27826689</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren AL, Digby RJ, Needham EJ. Neurological update: COVID-19. J Neurol. (2021) 268:4379&#x2013;87. doi: 10.1007/s00415-021-10581-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10581-y</ArticleId><ArticleId IdType="pmc">PMC8085652</ArticleId><ArticleId IdType="pubmed">33929617</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto A, Odoloni S, Masciocchi S, Cornelli A. Steroid-responsive encephalitis in coronavirus disease 2019. Ann Neurol. (2020) 88:423&#x2013;7. doi: 10.1002/ana.25783, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25783</ArticleId><ArticleId IdType="pmc">PMC7276848</ArticleId><ArticleId IdType="pubmed">32418288</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. (2020) 11:995&#x2013;8. doi: 10.1021/acschemneuro.0c00122, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00122</ArticleId><ArticleId IdType="pubmed">32167747</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARSCoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. (2020) 92:707&#x2013;9. doi: 10.1002/jmv.25728, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25728</ArticleId><ArticleId IdType="pmc">PMC7228344</ArticleId><ArticleId IdType="pubmed">32246783</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou JJ, Movassaghi M, Gordy D, Olson MG, Zhang T, Khurana MS, et al. . Neuropathology of COVID-19 (neuro-COVID): clinicopathological update. Free Neuropathol. (2021) 2:2. doi: 10.17879/freeneuropathology-2021-2993</Citation><ArticleIdList><ArticleId IdType="doi">10.17879/freeneuropathology-2021-2993</ArticleId><ArticleId IdType="pmc">PMC7861505</ArticleId><ArticleId IdType="pubmed">33554218</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorcet G, Benaiteau M, Bost C, Mengelle C, Bonneville F, Martin-Blondel G, et al. . Two cases of late-onset antiNMDAr auto-immune encephalitis after herpes simplex virus 1 encephalitis. Front Neurol. (2020) 11:38. doi: 10.3389/fneur.2020.00038</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00038</ArticleId><ArticleId IdType="pmc">PMC7040193</ArticleId><ArticleId IdType="pubmed">32132963</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J, Kremer S, Merdji H, Schenck M, Severac F, Clere-Jehl R, et al. . Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients. Crit Care. (2020) 24:491. doi: 10.1186/s13054-020-03200-1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03200-1</ArticleId><ArticleId IdType="pmc">PMC7414289</ArticleId><ArticleId IdType="pubmed">32771053</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou SH-Y, Beghi E, Helbok R, Moro E, Sampson J, Altamirano V, et al. . Global incidence of neurological manifestations among patients hospitalized with COVID-19-A report for the GCS-neuro COVID consortium and the ENERGY consortium. JAMA Neurol. (2021):4. doi: 10.1001/jamanetworkopen.2021.12131</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.12131</ArticleId><ArticleId IdType="pmc">PMC8114143</ArticleId><ArticleId IdType="pubmed">33974053</ArticleId></ArticleIdList></Reference><Reference><Citation>Felger JC. Imaging the role of inflammation in mood and anxiety related disorders. Curr Neuropharmacol. (2018) 16:533&#x2013;58. doi: 10.2174/1570159X15666171123201142, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X15666171123201142</ArticleId><ArticleId IdType="pmc">PMC5997866</ArticleId><ArticleId IdType="pubmed">29173175</ArticleId></ArticleIdList></Reference><Reference><Citation>E Silva NM, Barros-Arag&#xe3;o FG, De Felice FG, Ferreira ST. Inflammation at the crossroads of COVID-19, cognitive deficits and depression. Neuropharmacology. (2022) 209:109023. doi: 10.1016/j.neuropharm.2022.109023, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2022.109023</ArticleId><ArticleId IdType="pmc">PMC8894741</ArticleId><ArticleId IdType="pubmed">35257690</ArticleId></ArticleIdList></Reference><Reference><Citation>Esch T, Stefano GB. Proinflammation: A common denominator or initiator of different pathophysiological disease processes. Med Sci Monit. (2002) 8:HY1&#x2013;9. PMID:</Citation><ArticleIdList><ArticleId IdType="pubmed">12011758</ArticleId></ArticleIdList></Reference><Reference><Citation>Duindam HB, Kessels RPC, van den Borst B, Pickkers P, Abdo WF. Long-term cognitive performance and its relation to anti-inflammatory therapy in a cohort of survivors of severe COVID-19. Brain Behav Immun Health. (2022) 25:100513. doi: 10.1016/j.bbih.2022.100513, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2022.100513</ArticleId><ArticleId IdType="pmc">PMC9482799</ArticleId><ArticleId IdType="pubmed">36159208</ArticleId></ArticleIdList></Reference><Reference><Citation>Putilina MV, Grishin DV. SARS-CoV-2 (COVID-19) as a predictor of Neuroinflammation and neurodegeneration: potential treatment strategies. Neurosci Behav Physiol. (2021) 51:577&#x2013;82. doi: 10.1007/s11055-021-01108-z, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11055-021-01108-z</ArticleId><ArticleId IdType="pmc">PMC8219508</ArticleId><ArticleId IdType="pubmed">34176996</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, et al. . Persistent neurological symptoms and cognitive dysfunction in non-hospitalized Covid-19 &#x201c;long haulers&#x201d;. Ann Clin Transl Neurol. (2021) 10:1073: 1085. doi: 10.1002/acn3.51350</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51350</ArticleId><ArticleId IdType="pmc">PMC8108421</ArticleId><ArticleId IdType="pubmed">33755344</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung ML, Tan B, Cherian R, Chandra B. Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots. Rheumatol Adv Pract. (2021) 5:rkaa081. doi: 10.1093/rap/rkaa081, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rap/rkaa081</ArticleId><ArticleId IdType="pmc">PMC7882149</ArticleId><ArticleId IdType="pubmed">33615129</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu KE, Fazal FM, Parker KR, Zou J, Chang HY. RNA-GPS predicts SARS-CoV-2 RNA residency to host mitochondria and nucleolus. Cell Syst. (2020) 11:102&#x2013;108.e3. doi: 10.1016/j.cels.2020.06.008, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2020.06.008</ArticleId><ArticleId IdType="pmc">PMC7305881</ArticleId><ArticleId IdType="pubmed">32673562</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh KK, Chaubey G, Chen JY, Suravajhala P. Decoding SARS-CoV-2 hi&#xac;jacking of host mitochondria in COVID-19 pathogenesis. Am J Physiol Cell Physiol. (2020) 319:C258&#x2013;67. doi: 10.1152/ajpcell.00224.2020, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00224.2020</ArticleId><ArticleId IdType="pmc">PMC7381712</ArticleId><ArticleId IdType="pubmed">32510973</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefano GB, Esch T, Kream RM. Potential Immunoregulatory and antiviral/SARS-CoV-2 activities of nitric oxide. Med Sci Monit. (2020) 26:e925679. doi: 10.12659/MSM.925679, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.925679</ArticleId><ArticleId IdType="pmc">PMC7271680</ArticleId><ArticleId IdType="pubmed">32454510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell DB, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J. (2022) 479:537&#x2013;59. doi: 10.1042/BCJ20220016, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20220016</ArticleId><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsivgoulis G, Palaiodimou L, Zand R, Lioutas VA, Krogias C, Katsanos AH, et al. . COVID-19 and cerebrovascular diseases: a comprehensive overview. Ther Adv Neurol Disord. (2020) 13:1756286420978004. doi: 10.1177/1756286420978004, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756286420978004</ArticleId><ArticleId IdType="pmc">PMC7727052</ArticleId><ArticleId IdType="pubmed">33343709</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. . High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. (2020) 46:1089&#x2013;98. doi: 10.1007/s00134-020-06062-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06062-x</ArticleId><ArticleId IdType="pmc">PMC7197634</ArticleId><ArticleId IdType="pubmed">32367170</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabretta E, Moraleda JM, Iacobelli M, Jara R, Vlodavsky I, O'Gorman P, et al. . COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. Br J Haematol. (2021) 193:43&#x2013;51. doi: 10.1111/bjh.17240, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17240</ArticleId><ArticleId IdType="pmc">PMC8014053</ArticleId><ArticleId IdType="pubmed">33538335</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Persistent brainstem dysfunction in long-COVID: a hypothesis. ACS Chem Neurosci. (2021) 12:573&#x2013;80. doi: 10.1021/acschemneuro.0c00793, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00793</ArticleId><ArticleId IdType="pubmed">33538586</ArticleId></ArticleIdList></Reference><Reference><Citation>Holly JMP, Biernacka K, Maskell N, Perks CM. Obesity, diabetes and COVID-19: An infectious disease spreading from the east collides with the consequences of an unhealthy Western lifestyle. Front Endocrinol (Lausanne). (2020) 11:582870. doi: 10.3389/fendo.2020.582870, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.582870</ArticleId><ArticleId IdType="pmc">PMC7527410</ArticleId><ArticleId IdType="pubmed">33042029</ArticleId></ArticleIdList></Reference><Reference><Citation>Holly JM. Commentary: A machine-generated view of the role of blood glucose levels in the severity of COVID-19. A metabolic endocrinology perspective. Front Endocrinol. (2022) 13:13. doi: 10.3389/fendo.2022.877973</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.877973</ArticleId><ArticleId IdType="pmc">PMC9097450</ArticleId><ArticleId IdType="pubmed">35574035</ArticleId></ArticleIdList></Reference><Reference><Citation>Holman N, Knighton P, Kar P, O'Keefe J, Curley M, Weaver A, et al. . Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: A population-based cohort study. Lancet Diabetes Endocrinol. (2020) 8:823&#x2013;33. doi: 10.1016/S2213-8587(20)30271-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(20)30271-0</ArticleId><ArticleId IdType="pmc">PMC7426091</ArticleId><ArticleId IdType="pubmed">32798471</ArticleId></ArticleIdList></Reference><Reference><Citation>Codo AC, Davanzo GG, de Brito ML, de Souza GF, Muraro SP, Virgilio-da-Silva JV, et al. . Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1&#x3b1;/glycolysis-dependent axis. Cell Metab. (2020) 32:437&#x2013;46. doi: 10.1016/j.cmet.2020.07.007, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2020.07.007</ArticleId><ArticleId IdType="pmc">PMC7367032</ArticleId><ArticleId IdType="pubmed">32697943</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Mahmeed W, Al-Rasadi K, Banerjee Y, Ceriello A, Cosentino F, Galia M, et al. . Promoting a Syndemic approach for Cardiometabolic disease management during COVID-19: the CAPISCO international expert panel. Front Cardiovasc Med. (2021) 8:787761. doi: 10.3389/fcvm.2021.787761, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.787761</ArticleId><ArticleId IdType="pmc">PMC8715947</ArticleId><ArticleId IdType="pubmed">34977193</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller GE, Chen E, Sze J, Marin T, Arevalo JM, Doll R, et al. . A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-&#x3ba;B signaling. Biol Psychiatry. (2008) 64:266&#x2013;72. doi: 10.1016/j.biopsych.2008.03.017, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2008.03.017</ArticleId><ArticleId IdType="pmc">PMC2581622</ArticleId><ArticleId IdType="pubmed">18440494</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Torres-Macho J, Elvira-Mart&#xed;nez CM, Molina-Trigueros LJ, Sebasti&#xe1;n-Viana T, Hern&#xe1;ndez-Barrera V. Obesity is associated with a greater number of long-term post-COVID symptoms and poor sleep quality: A multicentre case-control study. Int J Clin Pract. (2021) 75:e14917. doi: 10.1111/ijcp.14917, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14917</ArticleId><ArticleId IdType="pmc">PMC8646300</ArticleId><ArticleId IdType="pubmed">34569684</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab. (2020) 22:1935&#x2013;41. doi: 10.1111/dom.14057, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14057</ArticleId><ArticleId IdType="pmc">PMC7264681</ArticleId><ArticleId IdType="pubmed">32314455</ArticleId></ArticleIdList></Reference><Reference><Citation>Liptak P, Baranovicova E, Rosolanka R, Simekova K, Bobcakova A, Vysehradsky R, et al. . Persistence of metabolomic changes in patients during post-COVID phase: A prospective, observational study. Meta. (2022) 12:641. doi: 10.3390/metabo12070641</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo12070641</ArticleId><ArticleId IdType="pmc">PMC9321209</ArticleId><ArticleId IdType="pubmed">35888766</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein SP, Paquin T, Pritsker A, Haber RS. Glucocorticoid-induced insulin resistance: dexamethasone inhibits the activation of glucose transport in rat skeletal muscle by both insulin-and non-insulin-related stimuli. Diabetes. (1995) 44:441&#x2013;5. doi: 10.2337/diab.44.4.441, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diab.44.4.441</ArticleId><ArticleId IdType="pubmed">7698514</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini AL, Carli G, Kiferle L, Piersanti P, Palumbo P, Morbelli S, et al. . Time-dependent recovery of brain hypometabolism in neuro-COVID-19 patients. Eur J Nucl Med Mol Imaging. (2022) 50:90&#x2013;102. doi: 10.1007/s00259-022-05942-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-022-05942-2</ArticleId><ArticleId IdType="pmc">PMC9388976</ArticleId><ArticleId IdType="pubmed">35984451</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietmann A, Putzer D, Beer R, Helbok R, Pfausler B, Nordin AJ, et al. . Cerebral glucose hypometabolism in tick-borne encephalitis, a pilot study in 10 patients. Int J Infect Dis. (2016) 51:73&#x2013;7. doi: 10.1016/j.ijid.2016.06.022, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2016.06.022</ArticleId><ArticleId IdType="pubmed">27418580</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarlott L, Heald E, Forton D. Hepatitis C virus infection, and neurological and psychiatric disorders&#x2013;A review. J Adv Res. (2017) 8:139&#x2013;48. doi: 10.1016/j.jare.2016.09.005, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jare.2016.09.005</ArticleId><ArticleId IdType="pmc">PMC5272938</ArticleId><ArticleId IdType="pubmed">28149649</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp JA, Dressing A, Blazhanets G, Bormann T, Rau A, Schwabenland M, et al. . Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. (2021) 144:1&#x2013;14. doi: 10.1093/brain/awab009</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab009</ArticleId><ArticleId IdType="pmc">PMC8083602</ArticleId><ArticleId IdType="pubmed">33822001</ArticleId></ArticleIdList></Reference><Reference><Citation>Magistretti PJ, Pellerin L. The contribution of astrocytes to the 18F-2-deoxyglucose signal in PET activation studies. Mol Psychiatry. (1996) 1:445&#x2013;52. PMID:</Citation><ArticleIdList><ArticleId IdType="pubmed">9154245</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer ER, Parent MJ, Souza DG, Leuzy A, Lecrux C, Kim HI, et al. . [(18)F] FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci. (2017) 20:393&#x2013;5. doi: 10.1038/nn.4492, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4492</ArticleId><ArticleId IdType="pmc">PMC5378483</ArticleId><ArticleId IdType="pubmed">28135241</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER. Astrocyte biomarkers in Alzheimer&#x2019;s disease. Trends Mol Med. (2019) 25:77&#x2013;95. doi: 10.1016/j.molmed.2018.11.006, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2018.11.006</ArticleId><ArticleId IdType="pubmed">30611668</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoessl AJ. Glucose utilization: still in the synapse. Nat Neurosci. (2017) 20:382&#x2013;4. doi: 10.1038/nn.4513, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4513</ArticleId><ArticleId IdType="pubmed">28230843</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana IC, Souza DG, Pellerin L, Souza DO, Zimmer ER. About the source and consequences of 18F-FDG brain PET hypometabolism in short and long COVID-19. Eur J Nucl Med Mol Imaging. (2021) 48:2674&#x2013;5. doi: 10.1007/s00259-021-05342-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05342-y</ArticleId><ArticleId IdType="pmc">PMC8019399</ArticleId><ArticleId IdType="pubmed">33813593</ArticleId></ArticleIdList></Reference><Reference><Citation>Haggstrom LR, Nelson JA, Wegner EA, Caplan GA. 2-18F-fluoro-2-deoxyglucose positron emission tomography in delirium. J Cereb Blood Flow Metab. (2017) 37:3556&#x2013;67. doi: 10.1177/0271678X17701764, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X17701764</ArticleId><ArticleId IdType="pmc">PMC5669345</ArticleId><ArticleId IdType="pubmed">28350285</ArticleId></ArticleIdList></Reference><Reference><Citation>Kas A, Soret M, Pyatigoskaya N, Habert MO, Hesters A, le Guennec L, et al. . The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur J Nucl Med Mol Imaging. (2021) 48:2543&#x2013;57. doi: 10.1007/s00259-020-05178-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-05178-y</ArticleId><ArticleId IdType="pmc">PMC7810428</ArticleId><ArticleId IdType="pubmed">33452633</ArticleId></ArticleIdList></Reference><Reference><Citation>Morbelli S, Ekmekcioglu O, Barthel H, Albert NL, Boellaard R, Cecchin D, et al. . COVID-19 and the brain: impact on nuclear medicine in neurology. Eur J Nucl Med Mol Imaging. (2020). doi: 10.1007/s00259-020-04965-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-04965-x</ArticleId><ArticleId IdType="pmc">PMC7375837</ArticleId><ArticleId IdType="pubmed">32700058</ArticleId></ArticleIdList></Reference><Reference><Citation>Verger A, Barthel H, Tolboom N, Fraioli F, Cecchin D, Albert NL, et al. . 2-[18F]-FDG PET for imaging brain involvement in patients with long COVID: perspective of the EANM neuroimaging committee. Eur J Nucl Med Mol Imaging. (2022) 49:3599&#x2013;606. doi: 10.1007/s00259-022-05913-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-022-05913-7</ArticleId><ArticleId IdType="pmc">PMC9286958</ArticleId><ArticleId IdType="pubmed">35840817</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazhenets G, Schroeter N, Bormann T, Thurow J, Wagner D, Frings L, et al. . Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J Nucl Med. (2021) 62:910&#x2013;5. doi: 10.2967/jnumed.121.262128, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.121.262128</ArticleId><ArticleId IdType="pmc">PMC8882885</ArticleId><ArticleId IdType="pubmed">33789937</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H, et al. . 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. (2021) 48:2823&#x2013;33. doi: 10.1007/s00259-021-05215-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05215-4</ArticleId><ArticleId IdType="pmc">PMC7837643</ArticleId><ArticleId IdType="pubmed">33501506</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollini M, Morbelli S, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, et al. . Long COVID hallmarks on [18F]FDGPET/CT: a case-control study. Eur J Nucl Med Mol Imaging. (2021) 48:3187&#x2013;97. doi: 10.1007/s00259-021-05294-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05294-3</ArticleId><ArticleId IdType="pmc">PMC7937050</ArticleId><ArticleId IdType="pubmed">33677642</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto A, Cristillo V, Cotti Piccinelli S, Zoppi N, Bonzi G, Sattin D, et al. . Long-term neurological manifestations of COVID-19: prevalence and predictive factors. Neurol Sci. (2021) 42:4903&#x2013;7. doi: 10.1007/s10072-021-05586-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05586-4</ArticleId><ArticleId IdType="pmc">PMC8439956</ArticleId><ArticleId IdType="pubmed">34523082</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand A, Campion JY, Lepine A, Bosdure E, Luciani L, Cammilleri S, et al. . Similar patterns of [18F]-FDG brain PET hypometabolism in paediatric and adult patients with long COVID: a paediatric case series. Eur J Nucl Med Mol Imaging. (2022) 49:913&#x2013;20. doi: 10.1007/s00259-021-05528-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05528-4</ArticleId><ArticleId IdType="pmc">PMC8376118</ArticleId><ArticleId IdType="pubmed">34414470</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer PT, Hellwig S, Blazhenets G, Hosp JA. Molecular imaging findings on acute and long-term effects of COVID-19 on the brain: a systematic review. J Nucl Med. (2022) 63:971&#x2013;80. doi: 10.2967/jnumed.121.263085, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.121.263085</ArticleId><ArticleId IdType="pmc">PMC9258567</ArticleId><ArticleId IdType="pubmed">35177424</ArticleId></ArticleIdList></Reference><Reference><Citation>Dressing A, Bormann T, Blazhenets G, Schroeter N, Walter LI, Thurow J, et al. . Neuropsychological profiles and cerebral glucose metabolism in neurocognitive long COVID-syndrome. J Nucl Med. (2021) 63:1058&#x2013;63. doi: 10.2967/jnumed.121.262677</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.121.262677</ArticleId><ArticleId IdType="pmc">PMC9258569</ArticleId><ArticleId IdType="pubmed">34649946</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer PT, Frings L, R&#xfc;cker G, Hellwig S. 18F-FDG PET in parkinsonism: differential diagnosis and evaluation of cognitive impairment. J Nucl Med. (2017) 58:1888&#x2013;98. doi: 10.2967/jnumed.116.186403, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.116.186403</ArticleId><ArticleId IdType="pubmed">28912150</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer&#x2019;s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. (2005) 32:486&#x2013;510. doi: 10.1007/s00259-005-1762-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-005-1762-7</ArticleId><ArticleId IdType="pubmed">15747152</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrer DS, Christian BT, Mantil J, Murray AC, Buchsbaum BR, Oakes TR, et al. . Thalamic and prefrontal FDG uptake in never medicated patients with schizophrenia. Am J Psychiatry. (2005) 162:931&#x2013;8. doi: 10.1176/appi.ajp.162.5.931, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.162.5.931</ArticleId><ArticleId IdType="pubmed">15863795</ArticleId></ArticleIdList></Reference><Reference><Citation>Morassi M, Palmerini F, Nici S, Magni E, Savelli G, Guerra UP, et al. . SARS-CoV-2-related encephalitis with prominent parkinsonism: clinical and FDG-PET correlates in two patients. J Neurol. (2021) 268:3980&#x2013;7. doi: 10.1007/s00415-021-10560-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10560-3</ArticleId><ArticleId IdType="pmc">PMC8059684</ArticleId><ArticleId IdType="pubmed">33884450</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon MN, Heneka MT, Le Page LM, Limberger C, Morgan D, Tenner AJ, et al. . Impact of COVID-19 on the onset and progression of Alzheimer's disease and related dementias: A roadmap for future research. Alzheimers Dement. (2022) 18:1038&#x2013;46. doi: 10.1002/alz.12488</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12488</ArticleId><ArticleId IdType="pmc">PMC9011667</ArticleId><ArticleId IdType="pubmed">34874605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Kream RM, Stefano GB. Long term respiratory and neurological sequelae of COVID-19. Med Sci Monit. (2020) 26:996. doi: 10.12659/MSM.928996, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.928996</ArticleId><ArticleId IdType="pmc">PMC7643287</ArticleId><ArticleId IdType="pubmed">33177481</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Castro PJ, Estivill-Torr&#xfa;s G, Cabezudo-Garc&#xed;a P, Reyes-Bueno JA, Ciano Petersen N, Aguilar-Castillo MJ, et al. . Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic? Neurologia. (2020) 35:245&#x2013;51. doi: 10.1016/j.nrl.2020.04.002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nrl.2020.04.002</ArticleId><ArticleId IdType="pmc">PMC7164900</ArticleId><ArticleId IdType="pubmed">32364119</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahill GF, Jr. Fuel metabolism in starvation. Annu Rev Nutr. (2006) 26:1&#x2013;22. doi: 10.1146/annurev.nutr.26.061505.111258, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.nutr.26.061505.111258</ArticleId><ArticleId IdType="pubmed">16848698</ArticleId></ArticleIdList></Reference><Reference><Citation>Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J. Effect of hyperketonemia and hyperlacticacidemia on symptoms, cognitive dysfunction, and counterregulatory hormone responses during hypoglycemia in normal humans. Diabetes. (1994) 43:1311&#x2013;7. doi: 10.2337/diab.43.11.1311, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diab.43.11.1311</ArticleId><ArticleId IdType="pubmed">7926305</ArticleId></ArticleIdList></Reference><Reference><Citation>Page KA, Williamson A, Yu N, McNay EC, Dzuira J, McCrimmon RJ, et al. . Medium-chain fatty acids improve cognitive function in intensively treated type 1 diabetic patients and support in vitro synaptic transmission during acute hypoglycemia. Diabetes. (2009) 58:1237&#x2013;44. doi: 10.2337/db08-1557, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db08-1557</ArticleId><ArticleId IdType="pmc">PMC2671041</ArticleId><ArticleId IdType="pubmed">19223595</ArticleId></ArticleIdList></Reference><Reference><Citation>Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia. (2007) 48:43&#x2013;58. doi: 10.1111/j.1528-1167.2007.00915.x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1528-1167.2007.00915.x</ArticleId><ArticleId IdType="pubmed">17241207</ArticleId></ArticleIdList></Reference><Reference><Citation>Puchalska P, Crawford PA. Metabolic and signaling roles of ketone bodies in health and disease. Ann Rev Nutri. (2021) 41:49&#x2013;77. doi: 10.1146/annurev-nutr-111120-111518, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-nutr-111120-111518</ArticleId><ArticleId IdType="pmc">PMC8922216</ArticleId><ArticleId IdType="pubmed">34633859</ArticleId></ArticleIdList></Reference><Reference><Citation>de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. N Engl J Med. (2019) 381:2541&#x2013;51. doi: 10.1056/NEJMra1905136, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1905136</ArticleId><ArticleId IdType="pubmed">31881139</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin L, Ipek &#xd6;, Beaumont M, Shevlyakova M, Christinat N, Masoodi M, et al. . Nutritional ketosis increases NAD+/NADH ratio in healthy human brain: an in vivo study by 31P-MRS. Front Nutr. (2018):62. doi: 10.3389/fnut.2018.00062</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2018.00062</ArticleId><ArticleId IdType="pmc">PMC6052097</ArticleId><ArticleId IdType="pubmed">30050907</ArticleId></ArticleIdList></Reference><Reference><Citation>Maalouf M, Rho JM, Mattson MP. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev. (2009) 59:293&#x2013;315. doi: 10.1016/j.brainresrev.2008.09.002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresrev.2008.09.002</ArticleId><ArticleId IdType="pmc">PMC2649682</ArticleId><ArticleId IdType="pubmed">18845187</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith CM, Eid T, Rose GM, Patrylo PR. Evidence for altered insulin receptor signaling in Alzheimer's disease. Neuropharmacology. (2018) 136:202&#x2013;15. doi: 10.1016/j.neuropharm.2018.01.008, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2018.01.008</ArticleId><ArticleId IdType="pubmed">29353052</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY, Ahima RS, et al. . Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. (2018) 14:168&#x2013;81. doi: 10.1038/nrneurol.2017.185, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.185</ArticleId><ArticleId IdType="pmc">PMC6098968</ArticleId><ArticleId IdType="pubmed">29377010</ArticleId></ArticleIdList></Reference><Reference><Citation>Son SM, Song H, Byun J, Park KS, Jang HC, Park YJ, et al. . Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions. Autophagy. (2012) 8:1842&#x2013;4. doi: 10.4161/auto.21861, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.21861</ArticleId><ArticleId IdType="pmc">PMC3541299</ArticleId><ArticleId IdType="pubmed">22931791</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, Alldred MJ, Ginsberg SD, Ohno M. Mechanisms underlying insulin deficiency-induced acceleration of &#x3b2;-amyloidosis in a mouse model of Alzheimer's disease. PLoS One. (2012) 7:e32792. doi: 10.1371/journal.pone.0032792, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0032792</ArticleId><ArticleId IdType="pmc">PMC3293895</ArticleId><ArticleId IdType="pubmed">22403710</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B, Backus C, Oh S, Hayes JM, Feldman EL. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology. (2009) 150:5294&#x2013;301. doi: 10.1210/en.2009-0695, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2009-0695</ArticleId><ArticleId IdType="pmc">PMC2795717</ArticleId><ArticleId IdType="pubmed">19819959</ArticleId></ArticleIdList></Reference><Reference><Citation>Puig KL, Floden AM, Adhikari R, Golovko MY, Combs CK. Amyloid precursor protein and proinflammatory changes are regulated in brain and adipose tissue in a murine model of high fat diet-induced obesity. PLoS One. (2012) 7:e30378. doi: 10.1371/journal.pone.0030378, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0030378</ArticleId><ArticleId IdType="pmc">PMC3261903</ArticleId><ArticleId IdType="pubmed">22276186</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato K, Kashiwaya Y, Keon CA, Tsuchiya N, King MT, Radda GK, et al. . Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J. (1995) 9:651&#x2013;8. doi: 10.1096/fasebj.9.8.7768357, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fasebj.9.8.7768357</ArticleId><ArticleId IdType="pubmed">7768357</ArticleId></ArticleIdList></Reference><Reference><Citation>Tardif A, Julien N, Pelletier A, Thibault G, Srivastava AK, Chiasson JL, et al. . Chronic exposure to &#x3b2;-hydroxybutyrate impairs insulin action in primary cultures of adult cardiomyocytes. Am J Physiol Endocrinol Metabolism. (2001) 281:E1205&#x2013;12. doi: 10.1152/ajpendo.2001.281.6.E1205, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.2001.281.6.E1205</ArticleId><ArticleId IdType="pubmed">11701435</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xfc;rtz P, M&#xe4;kinen VP, Soininen P, Kangas AJ, Tukiainen T, Kettunen J, et al. . Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes. (2012) 61:1372&#x2013;80. doi: 10.2337/db11-1355, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db11-1355</ArticleId><ArticleId IdType="pmc">PMC3357275</ArticleId><ArticleId IdType="pubmed">22511205</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacourt TE, Vichaya EG, Chiu GS, Dantzer R, Heijnen CJ. The high costs of low-grade inflammation: persistent fatigue as a consequence of reduced cellular-energy availability and non-adaptive energy expenditure. Front Behav Neurosci. (2018):78. doi: 10.3389/fnbeh.2018.00078</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnbeh.2018.00078</ArticleId><ArticleId IdType="pmc">PMC5932180</ArticleId><ArticleId IdType="pubmed">29755330</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohnuma T, Toda A, Kimoto A, Takebayashi Y, Higashiyama R, Tagata Y, et al. . Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer&#x2019;s disease: a prospective, open-label pilot study. Clin Interv Aging. (2016) 11:29. doi: 10.2147/CIA.S95362, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S95362</ArticleId><ArticleId IdType="pmc">PMC4712972</ArticleId><ArticleId IdType="pubmed">26811674</ArticleId></ArticleIdList></Reference><Reference><Citation>Ota M, Matsuo J, Ishida I, Takano H, Yokoi Y, Hori H, et al. . Effects of a medium-chain triglyceride-based ketogenic formula on cognitive function in patients with mild-to-moderate Alzheimer&#x2019;s disease. Neurosci Lett. (2019) 690:232&#x2013;6. doi: 10.1016/j.neulet.2018.10.048, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2018.10.048</ArticleId><ArticleId IdType="pubmed">30367958</ArticleId></ArticleIdList></Reference><Reference><Citation>Avgerinos KI, Egan JM, Mattson MP, Kapogiannis D. Medium chain triglycerides induce mild ketosis and may improve cognition in Alzheimer's disease. A systematic review and meta-analysis of human studies. Ageing Res Rev. (2020) 58:101001. doi: 10.1016/j.arr.2019.101001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2019.101001</ArticleId><ArticleId IdType="pmc">PMC7050425</ArticleId><ArticleId IdType="pubmed">31870908</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Auwera I, Wera S, Van Leuven F, Henderson ST. A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. Nutrit Metabol. (2005) 2:1&#x2013;8. doi: 10.1186/1743-7075-2-28</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-7075-2-28</ArticleId><ArticleId IdType="pmc">PMC1282589</ArticleId><ArticleId IdType="pubmed">16229744</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashiwaya Y, Bergman C, Lee JH, Wan R, King MT, Mughal MR, et al. . A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease. Neurobiol Aging. (2013) 34:1530&#x2013;9. doi: 10.1016/j.neurobiolaging.2012.11.023, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.11.023</ArticleId><ArticleId IdType="pmc">PMC3619192</ArticleId><ArticleId IdType="pubmed">23276384</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>